Table 1.
Baseline characteristics of patients.
| Variable * | All Patients (n = 103) | GALNT14 “GG” (n = 21) | GALNT14 “Non-GG” (n = 82) | p-Value † |
|---|---|---|---|---|
| Gender | 0.816 | |||
| Male | 66 (64%) | 13 (61.9%) | 53 (64.6%) | |
| Female | 37 (36%) | 8 (38.1%) | 29 (35.4%) | |
| Ages of resection (y) | 64.0 ± 10.5 | 62.5 ± 11.7 | 64.4 ± 10.2 | 0.460 |
| CEA | 3.1 (0.9–65.2) | 3.1 (0.9–65.2) | 3.1 (0.9–64.3) | 0.577 |
| CA19-9 | 198.7 (2–20310.4) | 162.7 (2–8515.9) | 205 (2–20310.4) | 0.716 |
| T-bilirubin | 2.6 (0.3–23.7) | 2.9 (0.5–12.1) | 2.4 (0.3–23.7) | 0.923 |
| Tumor location | 0.491 | |||
| Head | 73 (72.3%) | 16 (76.2%) | 57 (71.3%) | |
| Body | 15 (14.9%) | 4 (19.0%) | 11 (13.8%) | |
| Tail | 13 (12.9%) | 1 (4.8%) | 12 (15%) | |
| Tumor size (cm3) | 14.1 (0.5–2535) | 6 (0.5–130.6) | 14.3 (0.8–2535) | 0.145 |
| Free margin | 0.374 | |||
| Positive (0 mm) | 27 (30.7%) | 5 (26.3%) | 22 (31.9%) | |
| Very close (0–3 mm) | 14 (15.9%) | 5 (26.3%) | 9 (13.0%) | |
| Negative (>3 mm) | 47 (53.4%) | 9 (47.4%) | 38 (55.1%) | |
| Differentiation | 0.881 | |||
| Well | 18 (17.6%) | 4 (19.0%) | 14 (17.3%) | |
| Moderate | 66 (64.7%) | 13 (61.9%) | 53 (65.4%) | |
| Poor | 18 (17.6%) | 4 (19.0%) | 14 (17.3%) | |
| Tumor invasion | 0.198 | |||
| pT1–3 | 94 (91.3%) | 21 (100%) | 73 (89%) | |
| pT4 | 9 (8.7%) | 0 (0%) | 9 (11%) | |
| Regional LN | 0.814 | |||
| N0 | 43 (41.7%) | 8 (38.1%) | 35 (42.7%) | |
| N1 | 53 (51.5%) | 12 (57.1%) | 41 (50%) | |
| N2 | 7 (6.8%) | 1 (4.8%) | 6 (7.3%) | |
| Metastasis | 0.501 | |||
| M0 | 88 (85.4%) | 17 (81%) | 71 (86.6%) | |
| M1 | 15 (14.6%) | 4 (19%) | 11 (13.4%) | |
| Peritoneal invasion | 1.000 | |||
| No | 99 (96.1%) | 20 (95.2%) | 79 (96.3%) | |
| Yes | 4 (3.9%) | 1 (4.8%) | 3 (3.7%) | |
| Vascular invasion | 0.232 | |||
| No | 78 (75.7%) | 18 (85.7%) | 60 (73.2%) | |
| Yes | 25 (24.3%) | 3 (14.3%) | 22 (26.8%) | |
| Lymphatic invasion | 0.705 | |||
| No | 38 (36.9%) | 7 (33.3%) | 31 (37.8%) | |
| Yes | 65 (63.1%) | 14 (66.7%) | 51 (62.2%) | |
| Perineural invasion | 0.136 | |||
| No | 28 (27.2%) | 3 (14.3%) | 25 (30.5%) | |
| Yes | 75 (72.8%) | 18 (85.7%) | 57 (69.5%) | |
| Adjuvant C/T | 0.153 | |||
| No | 72 (69.9%) | 12 (57.1%) | 60 (73.2%) | |
| Yes | 31 (30.1%) | 9 (42.9%) | 22 (26.8%) |
Abbreviations: y = year, CEA = carcinoembryonic antigen, CA 19-9 = carbohydrate antigen 19-9, T-bilirubin = total bilirubin, pT1–3 = different tumor size, location and invasion, LN = lymph node, C/T = chemotherapy, and GALNT14 = Nacetylgalactosaminyltransferase14. * Values were expressed as the mean ± standard deviation, if normally distributed, and median (range), if not normally distributed. Categorical data were expressed in number (percentage). † Comparison between the GALNT14 ‘‘GG’’ and ‘‘non-GG’’ genotypes.